Novel pharmacological targets for the treatment of Parkinson's disease

Nature Reviews Drug Discovery

Volumn 5, Issue 10, 2006, Pages 845-854

  Schapira, Anthony H V ^a,b   Bezard, Erwan ^c   Brotchie, Jonathan ^d   Calon, Frédéric ^e,f   Collingridge, Graham L ^g   Ferger, Borris ^h   Hengerer, Bastian ^h   Hirsch, Etienne ^i,j   Jenner, Peter ^k   Novère, Nicolas Le ^l   Obeso, José A ^m   Schwarzschild, Michael A ⁿ   Spampinato, Umberto ^c   Davidai, Giora ^o  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CNRS   (France)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ INSERM   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^m UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o Clinical and Scientific Affairs ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACP 103; AMPA RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; APOMORPHINE; BUSPIRONE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; E 2007; ENZYME INHIBITOR; GLUTAMATE RECEPTOR AGONIST; GYKI 47261; LEVODOPA; LISURIDE; MEMANTINE; METHYSERGIDE; MIRTAZAPINE; N PHENYL 7 (HYDROXYLIMINO)CYPROPA[B]CHROMEN 1A CARBOXAMIDE; QUETIAPINE; RIVASTIGMINE; ROTIGOTINE; SARIZOTAN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TALAMPANEL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG TARGETING; DYSKINESIA; HUMAN; INVOLUNTARY MOVEMENT; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANTIPARKINSON AGENTS; CHOLINERGIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MONOAMINE OXIDASE INHIBITORS; NARCOTIC ANTAGONISTS; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 33749247103     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2087     Document Type: Review

References (119)

1. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
2. Rascol, O. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 34, 1484-1491 2000).
3. Holloway, R. G. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Arch. Neurol. 61, 1044-1053 (2004).
4. Katzenschlager, R. et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Mov. Disord. 20, 151-157 (2005).
5. Poewe, W. & Luessi, F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 65, S11-S14 (2005).
6. Newman-Tancredi, A. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and α(1)/α(2)-adrenoceptor. J. Pharmacol. Exp. Ther. 303, 805-814 (2002).
7. Jenner, P. in Principles of Treatment in Parkinson's Disease (eds Schapira, A. H. V. & Olanow, C. W.) 33-359 (Elsevier, Philadelphia, 2005).
8. Fahn, S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. 252 (Suppl. 4), iv37-iv42 (2005).
9. Olanow, W., Schapira, A. H. & Rascol, O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23, S117-S126 (2000).
10. Calon, F. et al. Dopamine-receptor stimulation: Biobehavioral and biochemical consequences. Trends Neurosci. 23, S92-S100 (2000).
11. Brooks, D. J. & Sagar, H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry 74, 1071-1079 (2003).
12. Mercuri, N. B. & Bernardi, G. The 'magic' of L-dopa: Why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. 26, 341-344 (2005).
13. Perry, E. K. et al. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. Neurol. Transm. Park. Dis. Dement. Sect. 2, 149-158 (1990).
14. Asahina, M. et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol. Scand. 91, 437-443 (1995).
15. Quik, M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27, 561-568 (2004).
16. Rodriguez-Puertas, R., Pazos, A. & Pascual, J. Cholinergic markers in degenerative parkinsonism: Autoradiographic demonstration of high-affinity choline uptake carrier hyperactivity. Brain Res. 636, 327-332 (1994).
17. Katzenschlager, R. et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. CD003735 (2003).
18. Leroi, I. et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int. J. Geriatr. Psychiatry 19, 1-8 (2004).
19. Aarsland, D. et al. Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. J. Neurol. Neurosurg. Psychiatry 72, 708-712 (2002).
20. Emre, M. et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509-2518 (2004).
21. Werber, E. A. & Rabey, J. M. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J. Neural Transm. 108, 1319-1325 (2001).
22. Fabbrini, G. et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol. Sci. 23, 41-43 (2002).
23. Le Novere, N., Zoli, M. & Changeux, J. P. Neuronal nicotinic receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurosci. 8, 2428-2439 (1996).
24. Costa, G., Abin-Carriquiry, J. A. & Dajas, F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336-342 (2001).
25. Jeyarasasingam, G., Tompkins, L. & Quik, M. Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 109, 275-285 (2002).
26. Allam, M. F. et al. Smoking and Parkinson's disease: Systematic review of prospective studies. Mov. Disord. 19, 614-621 (2004).
27. Lucas, G., Bonhomme, N., De Deurwaerdère, P., Le Moal, M. & Spampinato, U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131, 57-63 (1997).
28. De Deurwaerdère, P. & Spampinato, U. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73, 1033-42 (1999).
29. De Deurwaerdère, P., Navailles, S., Berg, K. A., Clarke, W. P. & Spampinato, U. Constitutive activity of the serotonin 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 24, 3235-3241 (2004).
30. Nicholson, S. L. & Brotchie, J. M. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 9 (Suppl. 3), 1-6 (2002).
31. Frechilla, D. et al. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39, 288-296 (2001).
32. Numan, S. et al. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res. Mol. Brain Res 29, 391-396 (1995).
33. Fox, S. H. & Brotchie, J. M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord. 15, 1064-1069 (2000).
34. Bibbiani, F., Oh, J. D. & Chase, T. N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 57, 1829-1834 (2001).
35. Chassain, C. & Durif, F. M. Modulation of serotonin receptors in MPTP-lesioned monkeys. Mov. Disord. 19, 412 (2004).
36. Olanow, C. W. et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27, 58-62 (2004).
37. Bara-Jimenez, W. et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 20, 932-936 (2005).
38. Bonifati, V. et al. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 17, 73-82 (1994).
39. Oh, J. D., Bibbiani, F. & Chase, T. N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol. 177, 557-564 (2002).
40. Fox, S. H., Moser, B. & Brotchie, J. M. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra tuna reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151, 35-49 (1998).
41. Fox, S. H. & Brotchie, J. M. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 398, 59-64 (2000).
42. Gomez-Mancilla, B. & Bedard, P. J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418-427 (1993).
43. Ashby, C. R. Jr. & Wang, R. Y. Pharmacological actions of the atypical antipsychotic drug dozapine: A review. Synapse 24, 349-394 (1996).
44. Bymaster, F. P. et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96 (1996).
45. Grondin, R. et al. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52, 771-776 (1999).
46. Durif, F. et al. Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study. Neurology 62, 381-388 (2004).
47. Katzenschlager, R. et al. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: A double blind cross over study. J. Neurol. Neurosurg. Psychiatry 75, 295-297 (2004).
48. Iravani, M. M. et al. 3,4-methylenedioxymethampheta mine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 23, 9107-9115 (2003).
49. Chung, K. A., Carlson, N. E. & Nutt, J. G. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 64, 1797-1798 (2005).
50. Meco, G. et al. Mirtazapine in L-dopa-induced dyskinesias. Clin. Neuropharmacol. 26, 179-181 (2003).
51. Parsons, C. G., Danysz, W. & Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38, 735-767 (1999).
52. Nash, J. E. et al. The NR2B-selective NMDA receptor antagonist CP-101, 606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 188, 471-479 (2004).
53. Hadj Tahar, A. et al. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis 15, 171-176 (2004).
54. Counihan, T. J. et al. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neurons. J. Comp. Neurol. 390, 91-101 (1998).
55. Feng, B. et al. Structure-activity analysis of a novel NR2C/ NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br. J. Pharmacol. 141, 508-516 (2004).
56. Picconi, B. et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature Neurosci. 6, 501-506 (2003).
57. Marino, M. J. et al. Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment. Proc. Natl Acad. Sci. USA 100, 13668-13673 (2003).
58. O'Neill, M. J. et al. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur. J. Pharmacol. 486, 163-174 (2004).
59. More, J. C. et al. Characterisation of UBP296: A novel, potent and selective kainate receptor antagonist. Neuropharmacology 47, 46-64 (2004).
60. A receptors in the striatopallidal complex. Brain Res. 680, 43-52 (1995).
61. Calon, F. et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18, 241-253 (2003).
62. Xu, K., Bastia, E. & Schwarzschild, M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 105, 267-310 (2005).
63. Jenner, P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs 14, 729-738 (2005).
64. Fink, J S. et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186-195 (1992).
65. Grondin, R.et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52, 1673-1637 (1999).
66. Mori, A. & Shindou, T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: A potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 61, S44-S48 (2003).
67. Bara-Jimenez, W. et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61, 293-296 (2003).
68. Hauser, R. A., Hubble, J. P. & Truong, D. D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61, 297-303 (2003).
69. Ascherio, A. & Chen, H. Caffeinated clues from epidemiology of Parkinson's disease. Neurology 61, S51-S54 (2003).
70. Chen, J. F. et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143 (2001).
71. Fredduzzi, S. et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22, 1054-1062 (2002).
72. Bibbiani, F. et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184, 285-294 (2003).
73. Fuxe, K. et al. Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease. Neurology 61, S19-S23 (2003).
74. Kachroo, A. et al. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci. 25, 10414-10419 (2005).
75. 2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29, 1451-161 (2004).
76. Bezard, E., Brotchie, J. M. & Gross, C. E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nature Rev. Neurosci. 2, 577-588 (2001).
77. Calon, F. et al. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J. Neuropathol. Exp. Neurol. 61, 186-196 (2002).
78. Henry, B. et al. μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Exp. Neurol. 171, 139-146 (2001).
79. Samadi, P., Gregoire, L. & Bedard, P. J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 45, 954-963 (2003).
80. Fox, S. et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov. Disord. 19, 554-560 (2004).
81. Rascol, O. et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov. Disord. 9, 437-440 (1994).
82. Hollt, V. Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26, 59-77 (1986).
83. Sadee, W., Wang, D. & Bilsky, E. J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci. 76, 1427-1437 (2005).
84. Simonds, W. F. The molecular basis of opioid receptor function. Endocr Rev. 9, 200-212 (1988).
85. Mansour, A. et al. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18, 22-29 (1995).
86. Schapira, A. H. Etiology of Parkinson's disease. Neurology 66, S10-S23 (2006).
87. Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 302, 819-822 (2003).
88. Shults, C. W. et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541-1550 (2002).
89. Hunot, S. & Flavell, R. A. Apoptosis. Death of a monopoly? Science 292, 865-866 (2001).
90. Chen, H. et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059-1064 (2003).
91. Schapira, A. H. Disease modification in Parkinson's disease. Lancet Neurol. 3, 362-368 (2004).
92. Iravani, M. M., Haddon, C. O., Cooper, J. M., Jenner, P. & Schapira, A. H. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 96, 1315-1321 (2006).
93. Gu, M. et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91, 1075-1081 (2004).
94. Whone, A. L. et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54, 93-101 (2003).
95. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653-1661 (2002).
96. Schapira, A. H. & Olanow, C. W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291, 358-364 (2004).
97. Mytilineou, C. & Cohen, G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J. Neurochem. 45, 1951-1953 (1985).
98. Tatton, W. G. & Greenwood, C. E. Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30, 666-672 (1991).
99. Chiueh, C. C., Huang, S. J. & Murphy, D. L. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: Suppression by clorgyline and deprenyl. Synapse 11, 346-348 (1992).
100. Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol. 243, 241-247 (1993).
101. Wu, R. M., Chen, R. C. & Chiueh, C. C. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann. NY Acad. Sci. 899, 255-261 (2000).
102. Tatton, W. G., Ju, W. Y., Holland, D. P., Tai, C. & Kwan, M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63, 1572-1575 (1994).
103. Wadia, J. S. et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl. J. Neurosci. 18, 932-947 (1998).
104. Parkinson Disease Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183 (1993).
105. Akao, Y. et al. An anti-Parkinson's disease drug, N-propargyl-1 (R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326, 105-108 (2002).
106. Am, O. B., Amit, T. & Youdim, M. B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355, 169-172 (2004).
107. Maruyama, W., Takahashi, T., Youdim, M. & Naoi, M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109, 467-481 (2002).
108. Jenner, P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 63 (Suppl. 2), S13-S22 (2004).
109. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566 (2004).
110. Grondin, R. et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191-2201 (2002).
111. Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773 (2000).
112. Kordower, J. H. et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424 (1999).
113. Nutt, J. G. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73 (2003).
114. Gill, S. S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Med. 9, 589-595 (2003).
115. Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459-466 (2006).
116. Barker, R. A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol. 5, 285-286 (2006).
117. Schapira, A. H. & Obeso, J. Timing of treatment initiation in Parkinson's disease: A need for reappraisal? Ann. Neurol. 59, 559-562 (2006).
118. Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol. 5, 235-245 (2006).
119. Lang, A. E. & Obeso, J. A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3, 309-316 (2004).